Your browser doesn't support javascript.
loading
Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations.
Salter, Sandra M; Li, Dani; Trentino, Kevin; Nissen, Lisa; Lee, Kenneth; Orlemann, Karin; Peters, Ian; Murray, Kevin; Leeb, Alan; Deng, Lucy.
Affiliation
  • Salter SM; School of Allied Health, The University of Western Australia, Perth, WA 6000, Australia.
  • Li D; MedAdvisor International Pty Ltd., Melbourne, VIC 3000, Australia.
  • Trentino K; Medical School, The University of Western Australia, Perth, WA 6000, Australia.
  • Nissen L; Centre for Business and Economics of Health, Faculty of Business, The University of Queensland, Brisbane, QLD 4000, Australia.
  • Lee K; School of Allied Health, The University of Western Australia, Perth, WA 6000, Australia.
  • Orlemann K; SmartVax, Perth, WA 6000, Australia.
  • Peters I; SmartVax, Perth, WA 6000, Australia.
  • Murray K; School of Population and Global Health, The University of Western Australia, Perth, WA 6000, Australia.
  • Leeb A; SmartVax, Perth, WA 6000, Australia.
  • Deng L; Illawarra Medical Centre, Perth, WA 6000, Australia.
Vaccines (Basel) ; 10(12)2022 Nov 25.
Article in En | MEDLINE | ID: mdl-36560426
Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1, 2, 3 and booster. We conducted active vaccine safety surveillance from 130 community pharmacies in Australia integrated with AusVaxSafety, between August 2021-April 2022. Main outcomes: AEFI at 0-3 days post-vaccination; medical review/advice at 3 days and 42 days post-vaccination; SARS-CoV-2 breakthrough infection by day 42. Of 110,024 completed day 3 surveys (43.6% response rate), 50,367 (45.8%) reported any AEFI (highest proportions: Pfizer 42%, primary dose 3; AstraZeneca 58.3%, primary dose 1; Moderna 65.4% and Novavax 58.8%, both primary dose 2). The most common AEFI reported across all doses/vaccines were local reactions, systemic aches and fatigue/tiredness. Overall, 2172/110,024 (2.0%) and 1182/55,329 (2.1%) respondents sought medical review at days 3 and 42, respectively, and 931/42,318 (2.2%) reported breakthrough SARS-CoV-2 infection at day 42. We identified similar AEFI profiles but at lower proportions than previously reported for Pfizer, AstraZeneca, Moderna and Novavax COVID-19 vaccines. Moderna vaccine was the most reactogenic and associated with higher AEFI proportions across primary doses 2, 3, and booster.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: Vaccines (Basel) Year: 2022 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: Vaccines (Basel) Year: 2022 Document type: Article Affiliation country: Country of publication: